Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report)'s stock price fell 3.4% during trading on Tuesday . The company traded as low as $10.10 and last traded at $10.30. 119,155 shares changed hands during mid-day trading, a decline of 64% from the average session volume of 333,757 shares. The stock had previously closed at $10.66.
Upstream Bio Price Performance
The business's 50-day moving average is $8.41 and its 200 day moving average is $11.56.
Upstream Bio (NASDAQ:UPB - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The business had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million. As a group, analysts forecast that Upstream Bio, Inc. will post -4.3 earnings per share for the current year.
Institutional Investors Weigh In On Upstream Bio
A number of large investors have recently modified their holdings of UPB. BNP Paribas Financial Markets bought a new stake in Upstream Bio during the fourth quarter worth about $25,000. US Bancorp DE purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $27,000. Legal & General Group Plc purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. purchased a new position in shares of Upstream Bio during the fourth quarter valued at approximately $30,000. Finally, Tower Research Capital LLC TRC purchased a new stake in Upstream Bio during the fourth quarter valued at approximately $47,000.
About Upstream Bio
(
Get Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
